Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

5 of Last Week's Biggest Winners

By Rick Munarriz - Apr 14, 2013 at 7:15AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These five stocks posted double-digit gains this past week.

What's better than momentum? Mo' momentum. Let's take a closer look at five of this past week's biggest scorchers.


April 12

Weekly Gain

ACADIA Pharmaceuticals ( ACAD 2.34% )



VirnetX Holdings ( VHC -2.34% )



The Active Network (NYSE: ACTV)



Exelixis ( EXEL 1.43% )



MagicJack VocalTec ( CALL )



Source: Barron's.

Let's start with ACADIA. The biotech soared after receiving an expedited review path from the FDA for its promising treatment of Parkinson's-related hallucinations. Investors will still have to be patient, as the application for reviewing pimavanserin won't happen until late next year. However, that's still far sooner than many were expecting.

VirnetX Holdings moved higher after the European Patent Office added a patent for third-party VPN certification to the company's already impressive portfolio of intellectual capital. After a disappointing ruling earlier this month in VirnetX's patent-infringement battle, it's good to see news that breaks the company's way.

The Active Network -- the leader in online registrations for triathlons, marathons, and other endurance events -- laced up its shoes and began running uphill after expanding its relationship with Ironman. A new three-year deal will build on Active's services through nearly 190 endurance events across five different brands.

Exelixis presented encouraging preclinical data on its lead compound's effectiveness in combating cancer tumors that have metastasized to the bone. In a presentation at the annual American Association for Cancer Research meeting, a poster revealed that treatment of tumor-bearing animals on cabozantinib resulted in inhibition of tumor growth.

Shares of magicJack VocalTec soared 12% a week earlier after posting its first annual operating profit since 1996. The rally continued this week, and it may be telephony pioneer itself ready to step up as a buyer. Bloomberg reported this week that magicJack's CEO has suggested expanding the company's stock-buyback program earlier this month.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

VirnetX Holding Corp Stock Quote
VirnetX Holding Corp
$2.93 (-2.34%) $0.07
Exelixis, Inc. Stock Quote
Exelixis, Inc.
$17.03 (1.43%) $0.24
Acadia Pharmaceuticals Stock Quote
Acadia Pharmaceuticals
$19.65 (2.34%) $0.45
VocalTec Communications Ltd. Stock Quote
VocalTec Communications Ltd.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.